Tiago Fauth
Stock Analyst at Wells Fargo
(3.25)
# 1,098
Out of 5,124 analysts
152
Total ratings
43.97%
Success rate
3.5%
Average return
Main Sectors:
Stocks Rated by Tiago Fauth
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Overweight | $171 → $217 | $174.04 | +24.68% | 9 | Oct 31, 2025 | |
| WVE Wave Life Sciences | Maintains: Overweight | $21 → $18 | $17.00 | +5.88% | 4 | Sep 4, 2025 | |
| UTHR United Therapeutics | Maintains: Equal-Weight | $295 → $414 | $487.25 | -15.03% | 7 | Sep 3, 2025 | |
| MNKD MannKind | Maintains: Overweight | $9 → $10 | $5.67 | +76.37% | 2 | Sep 3, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $79 → $73 | $75.96 | -3.90% | 5 | Aug 20, 2025 | |
| LQDA Liquidia | Maintains: Overweight | $25 → $31 | $34.49 | -10.12% | 3 | Aug 13, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $333 → $395 | $397.65 | -0.67% | 7 | Aug 1, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $88 → $65 | $23.00 | +182.61% | 8 | Jul 10, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $67 → $76 | $76.49 | -0.64% | 1 | Jun 30, 2025 | |
| SVRA Savara | Maintains: Overweight | $8 → $7 | $6.03 | +16.09% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $112 → $101 | $20.86 | +384.18% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $3 | $1.22 | +145.90% | 2 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $20.36 | +27.70% | 6 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $17 | $14.24 | +19.38% | 1 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $75 | $79.41 | -5.55% | 1 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $62 | $9.03 | +586.60% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $89 | $213.24 | -58.26% | 16 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $51 | $31.12 | +63.88% | 3 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $120 | $59.43 | +101.92% | 7 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $4 | $25.42 | -84.26% | 4 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $3.49 | +301.15% | 4 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $300 | $87.11 | +244.39% | 5 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $10.39 | +150.24% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $28 | $3.42 | +718.71% | 7 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $81 | $25.12 | +222.45% | 11 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8 | $0.57 | +1,309.20% | 5 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $1.15 | +1,117.39% | 2 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $34 | $1.13 | +2,908.85% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $150 | $23.01 | +551.89% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $43.83 | -33.84% | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $1.85 | +602.70% | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $13 | $2.05 | +534.15% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2.5 → $2 | $1.01 | +98.02% | 4 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $297 → $340 | $840.95 | -59.57% | 3 | Dec 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $265 → $259 | $327.31 | -20.87% | 1 | Apr 28, 2021 |
Insmed
Oct 31, 2025
Maintains: Overweight
Price Target: $171 → $217
Current: $174.04
Upside: +24.68%
Wave Life Sciences
Sep 4, 2025
Maintains: Overweight
Price Target: $21 → $18
Current: $17.00
Upside: +5.88%
United Therapeutics
Sep 3, 2025
Maintains: Equal-Weight
Price Target: $295 → $414
Current: $487.25
Upside: -15.03%
MannKind
Sep 3, 2025
Maintains: Overweight
Price Target: $9 → $10
Current: $5.67
Upside: +76.37%
PTC Therapeutics
Aug 20, 2025
Maintains: Overweight
Price Target: $79 → $73
Current: $75.96
Upside: -3.90%
Liquidia
Aug 13, 2025
Maintains: Overweight
Price Target: $25 → $31
Current: $34.49
Upside: -10.12%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Equal-Weight
Price Target: $333 → $395
Current: $397.65
Upside: -0.67%
Ultragenyx Pharmaceutical
Jul 10, 2025
Maintains: Overweight
Price Target: $88 → $65
Current: $23.00
Upside: +182.61%
BridgeBio Pharma
Jun 30, 2025
Maintains: Overweight
Price Target: $67 → $76
Current: $76.49
Upside: -0.64%
Savara
May 28, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $6.03
Upside: +16.09%
Mar 21, 2025
Maintains: Overweight
Price Target: $112 → $101
Current: $20.86
Upside: +384.18%
Mar 4, 2025
Maintains: Equal-Weight
Price Target: $4 → $3
Current: $1.22
Upside: +145.90%
Feb 27, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $20.36
Upside: +27.70%
Feb 20, 2025
Maintains: Overweight
Price Target: $18 → $17
Current: $14.24
Upside: +19.38%
Aug 22, 2024
Initiates: Overweight
Price Target: $75
Current: $79.41
Upside: -5.55%
Aug 11, 2023
Maintains: Outperform
Price Target: $63 → $62
Current: $9.03
Upside: +586.60%
Jun 14, 2023
Assumes: Neutral
Price Target: $89
Current: $213.24
Upside: -58.26%
Jun 14, 2023
Assumes: Outperform
Price Target: $51
Current: $31.12
Upside: +63.88%
Jun 14, 2023
Assumes: Outperform
Price Target: $120
Current: $59.43
Upside: +101.92%
May 23, 2023
Reiterates: Underperform
Price Target: $4
Current: $25.42
Upside: -84.26%
May 16, 2023
Reiterates: Outperform
Price Target: $14
Current: $3.49
Upside: +301.15%
May 16, 2023
Reiterates: Outperform
Price Target: $300
Current: $87.11
Upside: +244.39%
May 11, 2023
Reiterates: Outperform
Price Target: $26
Current: $10.39
Upside: +150.24%
May 5, 2023
Maintains: Outperform
Price Target: $34 → $28
Current: $3.42
Upside: +718.71%
May 5, 2023
Maintains: Neutral
Price Target: $70 → $81
Current: $25.12
Upside: +222.45%
Mar 24, 2023
Reiterates: Neutral
Price Target: $8
Current: $0.57
Upside: +1,309.20%
Mar 23, 2023
Reiterates: Outperform
Price Target: $14
Current: $1.15
Upside: +1,117.39%
Mar 10, 2023
Maintains: Outperform
Price Target: $38 → $34
Current: $1.13
Upside: +2,908.85%
Mar 10, 2023
Reiterates: Outperform
Price Target: $150
Current: $23.01
Upside: +551.89%
Jan 26, 2023
Initiates: Outperform
Price Target: $29
Current: $43.83
Upside: -33.84%
Dec 16, 2022
Initiates: Outperform
Price Target: $13
Current: $1.85
Upside: +602.70%
Nov 18, 2022
Downgrades: Neutral
Price Target: $25 → $13
Current: $2.05
Upside: +534.15%
May 13, 2022
Maintains: Underperform
Price Target: $2.5 → $2
Current: $1.01
Upside: +98.02%
Dec 20, 2021
Maintains: Neutral
Price Target: $297 → $340
Current: $840.95
Upside: -59.57%
Apr 28, 2021
Maintains: Outperform
Price Target: $265 → $259
Current: $327.31
Upside: -20.87%